KURA ONCOLOGY INC. - COMMON STOCK

Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

29 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

06 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

24 Jun 2021 08:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in JMP Securities Life Sciences Conference

10 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Appoints Carol Schafer to Board of Directors

04 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

13 May 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports First Quarter 2021 Financial Results

06 May 2021 16:04:00 By Nasdaq GlobeNewswire

Kura Oncology to Report First Quarter 2021 Financial Results

29 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

22 Mar 2021 16:08:47 By Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results

24 Feb 2021 07:20:00 By Nasdaq GlobeNewswire

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

24 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Four Upcoming Investor Conferences

18 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results

17 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference

07 Jan 2021 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Present at J.P. Morgan Healthcare Conference

06 Jan 2021 07:30:00 By Nasdaq GlobeNewswire